Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

"Women come significantly later to their cardiologists and have the same peri-procedural [alcohol septal ablation] complications and worse long-term outcomes, which are caused by their older age; ...

Novel mavacamten had a big impact on quality of life in obstructive hypertrophic cardiomyopathy, according to a secondary analysis of the EXPLORER-HCM trial. The cardiac myosin inhibitor improved ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Mavacamten, an investigational allosteric modulator of cardiac myosin, has proved superior to placebo for improving symptoms and reducing or eliminating obstruction of the left ventricle in patients ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first ...

Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...

Patients with oHCM experience significant variation in cardiovascular events, health care resource use, and costs across age, sex, race, and US region.

Living with any kind of heart-related disease can be worrisome, especially one with a range of symptoms, such as obstructive hypertrophic cardiomyopathy (HCM). This genetic condition causes a ...

The physical symptoms of obstructive hypertrophic cardiomyopathy (HCM) are very real, ranging from chest pain and shortness of breath to a racing heart, lightheadedness, and fatigue. But there’s also ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten (MyoKardia) is a novel, oral, allosteric modulator of cardiac myosin. This therapy was specifically ...